Placebo group regrowth rate in alopecia areata clinical trials: A systematic review and meta-analysis - 16/07/22
Doi : 10.1016/j.jaad.2021.12.009
Jane J. Han, BS a, b, Sheena Desai, BS a, c, Sara J. Li, BS a, c, Karen J. Lee, BS a, Carol Mita, MLIS d, Cara Joyce, PhD b, Arash Mostaghimi, MD, MPA, MPH a, ⁎ 
a Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
b Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois
c School of Medicine, Tufts University, Boston, Massachusetts
d Countway Library, Harvard Medical School, Boston, Massachusetts
∗Correspondence to: Arash Mostaghimi, MD, MPA, MPH, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115Department of DermatologyBrigham and Women's Hospital221 Longwood AvenueBostonMA02115
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
|
| Key words: alopecia areata; clinical trials; placebo group regrowth rate. |
|
| Reprints not available from the authors. |
© 2021
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 87 - N° 2
P. 389-390 - août 2022 Retour au numéro
Article précédent
- Incidence of skin cancers in patients with eczema treated with ultraviolet phototherapy
- Tashmeeta Ahad, Elle Yueqiao Wang, Yi A. Liu, Tim K. Lee, Harvey Lui, Richard I. Crawford, Sunil Kalia
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- Elena Peeva, Emma Guttman-Yassky, Anindita Banerjee, Rodney Sinclair, Lori Ann Cox, Linda Zhu, Hua Zhu, Michael Vincent, Brett King
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?